Table 3.
Recently approved combinations and upcoming drugs in the first line treatment for patients with metastatic renal cell carcinoma (RCC) combining VEGF/R and PD1/PDL1 inhibition. NR: Not reached; NRe: Not Reported.
| Treatment and Study | Checkmate 214 Nivolumab + Ipilimumab [10,114] |
MK426 Pembrolizumab + Axitinib [115] | IMmotion 151 Atezolizumab +bevacizumab [117] | JAVELIN RENAL 101 Avelumab + Axitinib [116] | CLEAR Pembrolizumab + Lenvatinib | CheckMate 9ER Nivolumab + Cabozantinib | Tivozanib + Nivolumab |
|---|---|---|---|---|---|---|---|
| Comparator arm | Sunitinib | Sunitinib | Sunitinb | Sunitinib | Sunitinib | Sunitinib | - |
| Primary endpoint | ORR PFS OS |
PFS OS |
PFS (Investigator) PDL1+ OS ITT |
PFS PDL1ve OS PDL1ve |
PFS | PFS | Safety/security |
| Results initially presented | ESMO 2017 | ASCO GU 2019 | ASCO GU 2018 | ESMO 2018 | Recruiting | Recruiting | Recruiting |
| Median Follow Up (months) | 32.4 | 12.8 | 15 | 9.9 | NRe | NRe | NRe |
| ORR (%) | 42 | 59.3 | 43 | 55.2 | NRe | NRe | NRe |
| PFS (months) | 11.6 | 15.2 | 11.2 | 13.8 | NRe | NRe | NRe |
| mOS (months) | NR | NR | NRe | NR | NRe | NRe | NRe |